Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer.

30. Mai 2005

Karthaus, M., Ballo, H., Abenhardt, W., Steinmetz, T., Geer, T., Schimke, J., Braumann, D., Behrens, R., Behringer, D., Kindler, M., Messmann, H., Boeck, H.-P., Greinwald, R., Kleeberg, U., 2005.

Oncology 68, 326–32. doi:10.1159/000086971

Abstract